These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1878844)

  • 21. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease.
    Wang CL; Wu YT; Liu CA; Lin MW; Lee CJ; Huang LT; Yang KD
    Pediatrics; 2003 Feb; 111(2):E140-7. PubMed ID: 12563087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic and therapeutic use of immunoglobulin for intravenous administration in patients with secondary immunodeficiencies associated with malignancies.
    Morell A; Barandun S
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S87-91. PubMed ID: 2840630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New aspects of therapy with standard immunoglobulin preparations].
    Briese V
    Zentralbl Gynakol; 1986; 108(21):1273-81. PubMed ID: 3811676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of glucocorticoids in Kawasaki disease.
    Miura M
    Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kawasaki disease: part II. Complications and treatment.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous immunoglobulin: a review.
    Eibl MM; Wedgwood RJ
    Immunodefic Rev; 1989; 1 Suppl():1-42. PubMed ID: 2698646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC; Aronoff SC
    Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
    Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
    Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kawasaki disease with thrombocytosis followed by thrombocytopenia purpura in the same patient.
    Lipnick RN; Luban NL
    Am J Dis Child; 1989 Feb; 143(2):139-40. PubMed ID: 2916479
    [No Abstract]   [Full Text] [Related]  

  • 32. Kawasaki disease: Medical therapies.
    Newburger JW
    Congenit Heart Dis; 2017 Sep; 12(5):641-643. PubMed ID: 28580631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kawasaki disease in Sicily: clinical description and markers of disease severity.
    Maggio MC; Corsello G; Prinzi E; Cimaz R
    Ital J Pediatr; 2016 Nov; 42(1):92. PubMed ID: 27806720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey.
    Uehara R; Yashiro M; Oki I; Nakamura Y; Yanagawa H
    Pediatr Int; 2007 Aug; 49(4):427-30. PubMed ID: 17587262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg) - report of seven cases and review of the literature.
    Sherer Y; Levy Y; Fabbrizzi F; Shoenfeld Y
    Eur J Intern Med; 2000 Apr; 11(2):85-88. PubMed ID: 10745151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
    Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S
    Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intravenous substitution with immunoglobulins].
    Zielinski CC; Eibl MM
    Wien Klin Wochenschr; 1991; 103(17):524-7. PubMed ID: 1949811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections.
    Ferrara G; Zumla A; Maeurer M
    Am J Med; 2012 Oct; 125(10):1036.e1-8. PubMed ID: 22608788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.